DZ2880A1 - Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant. - Google Patents

Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.

Info

Publication number: DZ2880A1
Authority: DZ; Algeria
Prior art keywords: alkynyl; derivatives; preparation; pharmaceutical compositions; compositions containing
Prior art date: 1998-08-27

Application number

DZ990180A

Other languages

English (en)

Inventor

La Susan Deborah Crega

Joseph Peter Lyssikatos

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1999-08-25

Publication date

2003-12-15

1999-08-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2880A1 publication Critical patent/DZ2880A1/fr

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DZ990180A 1998-08-27 1999-08-25 Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant. DZ2880A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9814598P	1998-08-27	1998-08-27

Publications (1)

Publication Number	Publication Date
DZ2880A1 true DZ2880A1 (fr)	2003-12-15

Family

ID=22267481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990180A DZ2880A1 (fr)	1998-08-27	1999-08-25	Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.

Country Status (40)

Country	Link
US (3)	US6150377A (fr)
EP (1)	EP1107963B1 (fr)
JP (1)	JP3495706B2 (fr)
KR (1)	KR20010072991A (fr)
CN (1)	CN1314904A (fr)
AP (1)	AP2001002079A0 (fr)
AT (1)	ATE321037T1 (fr)
AU (1)	AU4925499A (fr)
BG (1)	BG105365A (fr)
BR (1)	BRPI9913138B8 (fr)
CA (2)	CA2578326C (fr)
CO (1)	CO5130017A1 (fr)
CZ (1)	CZ2001660A3 (fr)
DE (1)	DE69930518T2 (fr)
DZ (1)	DZ2880A1 (fr)
EA (1)	EA200100135A1 (fr)
EE (1)	EE200100118A (fr)
ES (1)	ES2259237T3 (fr)
GE (1)	GEP20033001B (fr)
GT (1)	GT199900140A (fr)
HK (1)	HK1039123A1 (fr)
HR (1)	HRP20010142A2 (fr)
HU (1)	HUP0103228A3 (fr)
ID (1)	ID27562A (fr)
IL (1)	IL141239A0 (fr)
IS (1)	IS5818A (fr)
MA (1)	MA26680A1 (fr)
NO (1)	NO20010964L (fr)
NZ (1)	NZ509372A (fr)
OA (1)	OA11645A (fr)
PA (1)	PA8480101A1 (fr)
PE (1)	PE20000986A1 (fr)
PL (1)	PL346426A1 (fr)
SK (1)	SK2442001A3 (fr)
SV (1)	SV1999000141A (fr)
TN (1)	TNSN99162A1 (fr)
TR (1)	TR200101343T2 (fr)
UY (1)	UY25682A1 (fr)
WO (1)	WO2000012499A1 (fr)
ZA (1)	ZA200101173B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030114503A1 (en) *	1997-06-16	2003-06-19	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
HRP20000904A2 (en) *	1998-07-06	2001-12-31	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
ATE289602T1 (de) *	1998-08-27	2005-03-15	Pfizer Prod Inc	Quinolin-2-on-derivate verwendbar als antikrebsmittel
TR200101343T2 (tr) *	1998-08-27	2001-09-21	Pfizer Products Inc.	Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
KR20010102073A (ko)	1999-02-11	2001-11-15	실버스타인 아써 에이.	항암제로 유용한 헤테로아릴-치환된 퀴놀린-2-온 유도체
HN2000000266A (es)	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6838467B2 (en)	2000-02-24	2005-01-04	Janssen Pharmaceutica N. V.	Dosing regimen
JO2361B1 (en)	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
ATE321038T1 (de)	2000-09-25	2006-04-15	Janssen Pharmaceutica Nv	Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
JP4974439B2 (ja) *	2000-09-25	2012-07-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
WO2002024686A2 (fr) *	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Derives de la quinoleine et de la quinazoline 6-heterocyclylmethyle inhibiteurs de la farnesyle transferase
US7173040B2 (en)	2000-09-25	2007-02-06	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
DE60139080D1 (de)	2000-11-21	2009-08-06	Janssen Pharmaceutica Nv	Farnesyltransferase hemmende benzoheterocyclische derivate
AU2002218436A1 (en) *	2000-12-19	2002-07-01	Pfizer Products Inc.	Crystal forms of 6-((4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl) -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production
WO2002051835A1 (fr) *	2000-12-27	2002-07-04	Janssen Pharmaceutica N.V.	Quinoline 4-substituee inhibitrice de la transferase farnesyl et derives de quinazoline
AU2002236813A1 (en) *	2001-01-22	2002-07-30	Schering Corporation	Treatment of malaria with farnesyl protein transferase inhibitors
EA006770B1 (ru) *	2001-03-12	2006-04-28	Янссен Фармацевтика Н.В.	Способ получения соединений имидазола
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
AU2002257114A1 (en) *	2001-04-06	2002-10-21	Schering Corporation	Treatment of malaria with farsenyl protein transferase inhibitors
US20050165053A1 (en) *	2001-06-04	2005-07-28	Cytovia, Inc.	Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1408971A4 (fr)	2001-06-21	2006-01-25	Ariad Pharma Inc	Nouvelles quinoleines et leurs utilisations
US6740757B2 (en) *	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
EP1458720B1 (fr)	2001-12-19	2009-03-18	Janssen Pharmaceutica N.V.	Utilisation de derives de quinoline 1,8-anneles substitues avec des triazoles lies par le carbone en tant qu'inhibiteurs de farnesyl transferase
ATE364384T1 (de)	2002-03-22	2007-07-15	Janssen Pharmaceutica Nv	Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ATE336496T1 (de)	2002-04-15	2006-09-15	Janssen Pharmaceutica Nv	Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
JP3814285B2 (ja) *	2002-12-19	2006-08-23	ファイザー・インク	眼疾患の治療に有用なプロテインキナーゼ阻害剤としての２−（１ｈ−インダゾール−６−イルアミノ）−ベンズアミド化合物
JP4691041B2 (ja)	2003-11-20	2011-06-01	チルドレンズホスピタルメディカルセンター	Ｇｔｐアーゼ阻害剤および使用方法
WO2005089515A2 (fr) *	2004-03-18	2005-09-29	The Brigham And Women's Hospital, Inc.	Procedes de traitement des synucleinopathies
WO2005094830A1 (fr) *	2004-03-30	2005-10-13	Pfizer Products Inc.	Combinaisons d'inhibiteurs de transduction de signaux
ATE492544T1 (de) *	2004-08-26	2011-01-15	Pfizer	Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
GEP20104906B (en)	2004-08-26	2010-02-25	Pfizer	Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006021886A1 (fr) *	2004-08-26	2006-03-02	Pfizer Inc.	Composes aminoheteroaryles en tant qu'inhibiteurs des proteines tyrosine kinases
EP1815247B1 (fr)	2004-11-05	2013-02-20	Janssen Pharmaceutica NV	Utilisation therapeutique d'inhibiteurs de farnesyltransferase et procedes de controle de leur efficacite
US20060107555A1 (en) *	2004-11-09	2006-05-25	Curtis Marc D	Universal snow plow adapter
US20060281788A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006275528B2 (en)	2005-07-29	2012-03-08	Children's Hospital Medical Center	GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
KR101536506B1 (ko) *	2005-09-07	2015-07-14	암젠 프레몬트 인코포레이티드	액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
CA2623125A1 (fr)	2005-09-20	2007-03-29	Osi Pharmaceuticals, Inc.	Marqueurs biologiques predictifs d'une reaction anticancereuse aux inhibiteurs kinase du recepteur du facteur de croissance 1 analogue a l'insuline
EP1968591A4 (fr)	2005-12-23	2010-02-17	Link Medicine Corp	Traitement de formes de synucleinopathie
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
MX2008013533A (es)	2006-04-20	2009-01-15	Janssen Pharmaceutica Nv	Compuestos heterociclicos como inhibidores de c-fms cinasa.
EP2016070B1 (fr)	2006-04-20	2016-01-13	Janssen Pharmaceutica N.V.	Inhibiteurs de la c-fms kinase
MX2008013990A (es)	2006-05-09	2009-01-29	Pfizer Prod Inc	Derivados de cicloalquilamino acidos.
ES2392630T3 (es)	2006-08-21	2012-12-12	F. Hoffmann-La Roche Ag	Terapia antitumoral con anticuerpos anti-VEGF
EP2155197A4 (fr) *	2007-03-09	2011-10-12	Link Medicine Corp	Traitement des maladies de surcharge lysosomale
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
US8232402B2 (en)	2008-03-12	2012-07-31	Link Medicine Corporation	Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) *	2008-05-06	2009-11-12	Universität des Saarlandes	Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
MX2011005096A (es)	2008-11-13	2011-11-18	Link Medicine Corp	Derivados de azaquinolinona y usos de los mismos.
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010099139A2 (fr)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Thérapie anti-cancer combinée
WO2010099137A2 (fr)	2009-02-26	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés in situ pour surveiller l'état emt de cellules tumorales in vivo
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (fr)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2542893A2 (fr)	2010-03-03	2013-01-09	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
US20110275644A1 (en)	2010-03-03	2011-11-10	Buck Elizabeth A	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012116040A1 (fr)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (fr)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Polythérapie antinéoplasique
US9980942B2 (en)	2012-05-02	2018-05-29	Children's Hospital Medical Center	Rejuvenation of precursor cells
CN104870454B (zh)	2012-08-07	2020-03-03	詹森药业有限公司	用于制备杂环酯衍生物的方法
CN107266405A (zh)	2012-08-07	2017-10-20	詹森药业有限公司	用于制备c‑fms激酶抑制剂的方法
AR094403A1 (es)	2013-01-11	2015-07-29	Hoffmann La Roche	Terapia de combinación de anticuerpos anti-her3
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
EA201890512A1 (ru)	2015-08-17	2018-09-28	Кура Онколоджи, Инк.	Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
MX2018006781A (es)	2015-12-03	2018-11-09	Agios Pharmaceuticals Inc	Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
WO2017184968A1 (fr)	2016-04-22	2017-10-26	Kura Oncology, Inc.	Méthodes de sélection de patients atteints de cancer pour le traitement avec des inhibiteurs de farnésyltransférase
RS61745B1 (sr)	2016-11-03	2021-05-31	Kura Oncology Inc	Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
US11471538B2 (en)	2017-02-10	2022-10-18	INSERM (Institut National de la Santéet de la Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
KR102003179B1 (ko)	2017-02-21	2019-07-23	쿠라 온콜로지, 인크.	파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
US10137121B2 (en)	2017-02-21	2018-11-27	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es)	2017-08-07	2020-03-20	Kura Oncology Inc	Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
US10806730B2 (en)	2017-08-07	2020-10-20	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (fr)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
EP3873469A2 (fr)	2018-11-01	2021-09-08	Kura Oncology, Inc.	Méthodes de traitement du cancer avec des inhibiteurs de la farnésyltransférase
US20220071941A1 (en)	2018-12-21	2022-03-10	Kura Oncology, Inc.	Therapies for squamous cell carcinomas
WO2020180663A1 (fr)	2019-03-01	2020-09-10	Kura Oncology, Inc.	Méthodes de traitement du cancer à l'aide d'inhibiteurs de farnésyltransférase
US20220143006A1 (en)	2019-03-15	2022-05-12	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
SG11202110472WA (en)	2019-03-29	2021-10-28	Kura Oncology Inc	Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en)	2019-04-01	2022-06-02	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
US20220305001A1 (en)	2019-05-02	2022-09-29	Kura Oncology, Inc.	Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
EP4013402B1 (fr)	2019-08-16	2024-11-06	Children's Hospital Medical Center	Inhibiteurs de cdc42 pour utilisation dans le traitement de la dépression, de la sarcopénie ou de la fragilité associées à l'âge
WO2021155006A1 (fr)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
CN119968374A (zh) *	2022-09-22	2025-05-09	南开大学	三尖杉酯碱类衍生物及其药物组合物、制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
EE03484B1 (et) *	1995-12-08	2001-08-15	Janssen Pharmaceutica N.V.	Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
TR200101343T2 (tr) *	1998-08-27	2001-09-21	Pfizer Products Inc.	Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri

1999
- 1999-08-06 TR TR2001/01343T patent/TR200101343T2/xx unknown
- 1999-08-06 EE EEP200100118A patent/EE200100118A/xx unknown
- 1999-08-06 CA CA002578326A patent/CA2578326C/fr not_active Expired - Fee Related
- 1999-08-06 KR KR1020017002442A patent/KR20010072991A/ko not_active Ceased
- 1999-08-06 AT AT99933084T patent/ATE321037T1/de not_active IP Right Cessation
- 1999-08-06 CZ CZ2001660A patent/CZ2001660A3/cs unknown
- 1999-08-06 IL IL14123999A patent/IL141239A0/xx unknown
- 1999-08-06 OA OA1200100051A patent/OA11645A/en unknown
- 1999-08-06 HR HR20010142A patent/HRP20010142A2/hr not_active Application Discontinuation
- 1999-08-06 CA CA002341690A patent/CA2341690C/fr not_active Expired - Fee Related
- 1999-08-06 CN CN99810204A patent/CN1314904A/zh active Pending
- 1999-08-06 BR BRPI9913138A patent/BRPI9913138B8/pt not_active IP Right Cessation
- 1999-08-06 PL PL99346426A patent/PL346426A1/xx not_active Application Discontinuation
- 1999-08-06 EP EP99933084A patent/EP1107963B1/fr not_active Expired - Lifetime
- 1999-08-06 DE DE69930518T patent/DE69930518T2/de not_active Expired - Lifetime
- 1999-08-06 GE GEAP19995770A patent/GEP20033001B/en unknown
- 1999-08-06 NZ NZ509372A patent/NZ509372A/en unknown
- 1999-08-06 JP JP2000567527A patent/JP3495706B2/ja not_active Expired - Fee Related
- 1999-08-06 HU HU0103228A patent/HUP0103228A3/hu unknown
- 1999-08-06 AP APAP/P/2001/002079A patent/AP2001002079A0/en unknown
- 1999-08-06 ES ES99933084T patent/ES2259237T3/es not_active Expired - Lifetime
- 1999-08-06 ID IDW20010457A patent/ID27562A/id unknown
- 1999-08-06 AU AU49254/99A patent/AU4925499A/en not_active Abandoned
- 1999-08-06 SK SK244-2001A patent/SK2442001A3/sk unknown
- 1999-08-06 EA EA200100135A patent/EA200100135A1/ru unknown
- 1999-08-06 HK HK02100579.7A patent/HK1039123A1/zh unknown
- 1999-08-06 WO PCT/IB1999/001398 patent/WO2000012499A1/fr not_active Ceased
- 1999-08-10 PA PA19998480101A patent/PA8480101A1/es unknown
- 1999-08-24 GT GT199900140A patent/GT199900140A/es unknown
- 1999-08-25 TN TNTNSN99162A patent/TNSN99162A1/fr unknown
- 1999-08-25 MA MA25743A patent/MA26680A1/fr unknown
- 1999-08-25 DZ DZ990180A patent/DZ2880A1/fr active
- 1999-08-26 US US09/383,755 patent/US6150377A/en not_active Expired - Lifetime
- 1999-08-26 PE PE1999000862A patent/PE20000986A1/es not_active Application Discontinuation
- 1999-08-27 SV SV1999000141A patent/SV1999000141A/es not_active Application Discontinuation
- 1999-08-27 UY UY25682A patent/UY25682A1/es unknown
- 1999-08-27 CO CO99054519A patent/CO5130017A1/es unknown
2000
- 2000-07-27 US US09/628,039 patent/US6294552B1/en not_active Expired - Lifetime
2001
- 2001-01-19 IS IS5818A patent/IS5818A/is unknown
- 2001-02-12 ZA ZA200101173A patent/ZA200101173B/en unknown
- 2001-02-26 NO NO20010964A patent/NO20010964L/no not_active Application Discontinuation
- 2001-03-20 BG BG105365A patent/BG105365A/xx unknown
- 2001-07-06 US US09/900,401 patent/US6579887B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6294552B1 (en)	2001-09-25
BG105365A (en)	2001-11-30
US6579887B2 (en)	2003-06-17
EE200100118A (et)	2002-06-17
NO20010964D0 (no)	2001-02-26
CN1314904A (zh)	2001-09-26
DE69930518D1 (de)	2006-05-11
HUP0103228A2 (hu)	2002-02-28
UY25682A1 (es)	2000-03-31
CO5130017A1 (es)	2002-02-27
HRP20010142A2 (en)	2002-02-28
EP1107963A1 (fr)	2001-06-20
ES2259237T3 (es)	2006-09-16
HK1039123A1 (zh)	2002-04-12
DE69930518T2 (de)	2006-09-21
AU4925499A (en)	2000-03-21
TR200101343T2 (tr)	2001-09-21
GEP20033001B (en)	2003-06-25
CA2341690A1 (fr)	2000-03-09
NO20010964L (no)	2001-04-26
PA8480101A1 (es)	2003-06-30
ZA200101173B (en)	2002-04-12
NZ509372A (en)	2003-08-29
SK2442001A3 (en)	2002-10-08
AP2001002079A0 (en)	2001-03-31
BR9913138A (pt)	2001-05-08
CA2341690C (fr)	2007-04-17
US6150377A (en)	2000-11-21
CA2578326A1 (fr)	2000-03-09
SV1999000141A (es)	2000-07-06
ATE321037T1 (de)	2006-04-15
GT199900140A (es)	2001-02-14
PE20000986A1 (es)	2000-09-30
BR9913138B1 (pt)	2013-11-05
JP3495706B2 (ja)	2004-02-09
IS5818A (is)	2001-01-19
CA2578326C (fr)	2009-11-24
WO2000012499A1 (fr)	2000-03-09
CZ2001660A3 (cs)	2002-05-15
IL141239A0 (en)	2002-03-10
BRPI9913138B8 (pt)	2016-05-17
OA11645A (en)	2004-11-16
EP1107963B1 (fr)	2006-03-22
MA26680A1 (fr)	2004-12-20
KR20010072991A (ko)	2001-07-31
JP2002523504A (ja)	2002-07-30
ID27562A (id)	2001-04-12
PL346426A1 (en)	2002-02-11
TNSN99162A1 (fr)	2005-11-10
US20020128287A1 (en)	2002-09-12
EA200100135A1 (ru)	2001-08-27
HUP0103228A3 (en)	2003-01-28

Publication	Publication Date	Title
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr)	2004-03-27	Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2634A1 (fr)	2003-03-08	Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ3042A1 (fr)	2004-03-27	Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2708608B1 (fr)	1995-10-27	Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
DZ2407A1 (fr)	2003-01-04	Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
CY2537B1 (fr)	2006-06-28	Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2708606B1 (fr)	1995-10-27	Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr)	2004-03-27	Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr)	2002-12-02	Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2188A1 (fr)	2002-12-02	Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CH689805A8 (fr)	2000-02-29	Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.